Roche shows its Spirit
This article was originally published in The Gray Sheet
Executive Summary
Firm launches its Accu-Chek Spirit diabetes self-management system in the U.S. Oct. 10 following a lift of FDA's import ban on Roche insulin pumps. The hold - in effect since pump maker Disetronic Medical Systems, purchased by Roche in May 2003, received an FDA warning letter in June 2003 - was lifted Oct. 9 following inspection of the Swiss manufacturing site last year (1"The Gray Sheet" July 21, 2003, p. 7). Accu-Chek Spirit, cleared by FDA in 2005, is compact and can be programmed discreetly, the company says. The insulin pump already is sold in 30 countries. Roche is one of a number of firms striving to reach the U.S. market with continuous glucose monitoring technology, where it would compete with Medtronic's Paradigm and Guardian offerings and DexCom's STS system...
You may also be interested in...
Disetronic Swiss Facility QS Problems Draw Warning Letter, Import Alert
Roche Diagnostics is working with FDA to resolve quality systems issues uncovered at the Burgdorf, Switzerland facility of recently acquired insulin pump maker Disetronic Medical Systems
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.